Dabigatran therapy in Japanese NVAF patients results in a wide distribution of APTT values, particularly in those on a reduced dose, suggesting APTT could potentially help screen for bleeding risk.
No takes yet. Share an insight, caveat, or question.
APTT variability may support bleeding risk screening in dabigatran-treated NVAF; hypothesis-generating and requires prospective validation before practice change.
Suzuki et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: